000063152 001__ 63152
000063152 005__ 20190709135509.0
000063152 0247_ $$2doi$$a10.1038/s41598-017-13034-7
000063152 0248_ $$2sideral$$a101868
000063152 037__ $$aART-2017-101868
000063152 041__ $$aeng
000063152 100__ $$aEuba, B.
000063152 245__ $$aResveratrol therapeutics combines both antimicrobial and immunomodulatory properties against respiratory infection by nontypeable Haemophilus influenzae
000063152 260__ $$c2017
000063152 5060_ $$aAccess copy available to the general public$$fUnrestricted
000063152 5203_ $$aThe respiratory pathogen nontypeable Haemophilus influenzae (NTHi) is an important cause of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) that requires efficient treatments. A previous screening for host genes differentially expressed upon NTHi infection identified sirtuin-1, which encodes a NAD-dependent deacetylase protective against emphysema and is activated by resveratrol. This polyphenol concomitantly reduces NTHi viability, therefore highlighting its therapeutic potential against NTHi infection at the COPD airway. In this study, resveratrol antimicrobial effect on NTHi was shown to be bacteriostatic and did not induce resistance development in vitro. Analysis of modulatory properties on the NTHi-host airway epithelial interplay showed that resveratrol modulates bacterial invasion but not subcellular location, reduces inflammation without targeting phosphodiesterase 4B gene expression, and dampens ß defensin-2 gene expression in infected cells. Moreover, resveratrol therapeutics against NTHi was evaluated in vivo on mouse respiratory and zebrafish septicemia infection model systems, showing to decrease NTHi viability in a dose-dependent manner and reduce airway inflammation upon infection, and to have a significant bacterial clearing effect without signs of host toxicity, respectively. This study presents resveratrol as a therapeutic of particular translational significance due to the attractiveness of targeting both infection and overactive inflammation at the COPD airway.
000063152 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/SAF2012-31166$$9info:eu-repo/grantAgreement/ES/MINECO/SAF2015-66520-R
000063152 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000063152 590__ $$a4.122$$b2017
000063152 591__ $$aMULTIDISCIPLINARY SCIENCES$$b12 / 64 = 0.188$$c2017$$dQ1$$eT1
000063152 592__ $$a1.533$$b2017
000063152 593__ $$aMultidisciplinary$$c2017$$dQ1
000063152 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000063152 700__ $$aLópez-López, N.
000063152 700__ $$aRodríguez-Arce, I.
000063152 700__ $$aFernández-Calvet, A.
000063152 700__ $$0(orcid)0000-0002-5225-661X$$aBarberán, M.$$uUniversidad de Zaragoza
000063152 700__ $$aCaturla, N.
000063152 700__ $$aMartí, S.
000063152 700__ $$aDíez-Martínez, R.
000063152 700__ $$aGarmendia, J.
000063152 7102_ $$11009$$2773$$aUniversidad de Zaragoza$$bDpto. Patología Animal$$cÁrea Sanidad Animal
000063152 773__ $$g7, 1 (2017), 12860 [14 pp]$$pSci. rep.$$tScientific reports$$x2045-2322
000063152 8564_ $$s1682865$$uhttps://zaguan.unizar.es/record/63152/files/texto_completo.pdf$$yVersión publicada
000063152 8564_ $$s103960$$uhttps://zaguan.unizar.es/record/63152/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000063152 909CO $$ooai:zaguan.unizar.es:63152$$particulos$$pdriver
000063152 951__ $$a2019-07-09-11:50:31
000063152 980__ $$aARTICLE